

# PRECEPTORSHIP PROGRAMME

## Ovarian Cancer

**ESMO  
PRECEPTORSHIP**

**LISBON PORTUGAL  
15-16 SEPTEMBER 2023**

Multidisciplinary management, standards  
of care and future perspectives.

**Co-Chairs**

Nicoletta Colombo, Italy  
Philipp Harter, Germany

# ESMO PRECEPTORSHIP PROGRAMME OVARIAN CANCER

Multidisciplinary management, standards of care  
and future perspectives

Lisbon, Portugal  
15-16 September 2023

---

**CO-CHAIRS** Nicoletta Colombo, Italy  
Philipp Harter, Germany

**SPEAKERS** Christina Fotopoulou, United Kingdom  
Antonio González Martín, Spain  
Charlie Gourley, United Kingdom  
Roberta Lazzari, Italy  
Xavier Matias-Guiu, Spain  
Xavier Paoletti, France  
Isabelle L. Ray-Coquard, France

---

## LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of early and late stage ovarian cancer
- To understand the importance of biology and pathology of common and rare ovarian tumours
- To understand the options for treatment of recurrent disease and how treatment decisions are made
- To understand the novel therapeutic agents being developed to treat ovarian cancer and how knowledge of genomics and molecular pathways guides drug development
- To learn about the management of patients with symptoms of the disease and the side effects of treatment

---

## ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.  
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4, 6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Friday, 15 September 2023

<b>09:00-09:10</b> 10'	<b>Welcome and introduction</b>	<b>Nicoletta Colombo, IT</b> <b>Philipp Harter, DE</b>
<b>09:10-09:30</b> 20'	<b>SESSION 1</b> <b>Early stage – Part I</b>	<b>Nicoletta Colombo, IT</b> <b>Philipp Harter, DE</b>
20'	Clinical management of early ovarian cancer	Isabelle L. Ray-Coquard, FR
<b>09:30-10:25</b> 55'	<b>SESSION 2</b> <b>Rare cancers – Part I</b>	<b>Nicoletta Colombo, IT</b> <b>Philipp Harter, DE</b>
20'	Germ cells tumours	Isabelle L. Ray-Coquard, FR
20'	Sex-cord stromal tumours	Isabelle L. Ray-Coquard, FR
15'	Q&A	All
<b>10:25-10:55</b>	<b>Coffee break</b>	
<b>10:55-13:00</b> 125'	<b>SESSION 3</b> <b>Advanced disease at diagnosis</b>	<b>Nicoletta Colombo, IT</b> <b>Philipp Harter, DE</b>
20'	Biology of high-grade tubo-epithelial cancers, including biomarkers in practice	Xavier Matias-Guiu, ES
20'	Surgery for newly diagnosed advanced ovarian cancer	Christina Fotopoulou, UK
40'	First-line chemotherapy (including maintenance) treatment	Nicoletta Colombo, IT
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
<b>13:00-14:00</b>	<b>Lunch</b>	
<b>14:00-15:00</b> 60'	<b>SESSION 4</b> <b>Early stage – Part II</b>	<b>Nicoletta Colombo, IT</b> <b>Philipp Harter, DE</b>
20'	Overview on pathology, classification of early epithelial carcinoma	Xavier Matias-Guiu, ES
10'	Q&A	All
20'	Surgery for early ovarian cancer: Staging	Philipp Harter, DE
10'	Q&A	All
<b>15:00-15:30</b> 30'	<b>SESSION 5</b> <b>Rare cancers – Part II</b>	<b>Nicoletta Colombo, IT</b> <b>Philipp Harter, DE</b>
20'	Rare epithelial tumours: Low-grade serous, clear cell and mucinous	Charlie Gourley, UK
10'	Q&A	All
<b>15:30-16:00</b>	<b>Coffee break</b>	

<b>16:00-18:05</b> <b>125'</b>	<b>SESSION 6</b> <b>Recurrent disease and complex cases – Part I</b>	<b>Charlie Gourley, UK</b> <b>Philipp Harter, DE</b>
20'	The role of surgery in recurrent ovarian cancer	Philipp Harter, DE
40'	Overview of systemic treatment for recurrent ovarian cancer: platinum-based and platinum-free	Nicoletta Colombo, IT
20'	The role of radiotherapy in ovarian cancer	Roberta Lazzari, IT
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
<b>19:30</b>	<b>Dinner</b>	

## Saturday, 16 September 2023

<b>09:00-10:15</b> <b>75'</b>	<b>SESSION 7</b> <b>Recurrent disease and complex cases – Part II</b>	<b>Nicoletta Colombo, IT</b> <b>Charlie Gourley, UK</b>
20'	Management of ovarian cancer in older and frail patients	Antonio González Martín, ES
20'	Fertility-sparing surgery: A clinical case	Nicoletta Colombo, IT
20'	Role of HIPEC in ovarian cancer	Philipp Harter, DE
15'	Q&A	All
<b>10:15-10:45</b>	<b>Coffee break</b>	
<b>10:45-12:05</b> <b>80'</b>	<b>SESSION 8</b> <b>Biology and methodologies: All we need to develop future strategies</b>	<b>Antonio González Martín, ES</b> <b>Charlie Gourley, UK</b>
40'	Drug resistance and how to overcome PARP inhibitors resistance	Charlie Gourley, UK
25'	Clinical trial design, meta-analysis, PRO and QoL	Xavier Paoletti, FR
15'	Q&A	All
<b>12:05-12:45</b> <b>40'</b>	<b>SESSION 9</b> <b>Future treatments</b>	<b>Nicoletta Colombo, IT</b> <b>Philipp Harter, DE</b>
25'	Novel treatment pathways and combinations: Horizon scanning	Antonio González Martín, ES
15'	Q&A	All
<b>12:45-13:00</b> <b>15'</b>	<b>Conclusion and farewell</b>	<b>Nicoletta Colombo, IT</b> <b>Philipp Harter, DE</b>
<b>13:00-14:00</b>	<b>Lunch</b>	

**Note:** Each 10 -minute slot for clinical case discussion includes a 5' case presentation and 5' Q&A / panel discussion